Uveitis – Global Drug Forecast and Market Analysis to 2029

Corticosteroids are typically the first line of therapy for most patients with uveitis as these drugs are very effective and have anti-inflammatory effects. However, as corticosteroids are associated with the development of cataracts and changes in intraocular pressures, it is becoming increasingly common for other immunosuppressants such as antimetabolites and calcineurin inhibitors to be prescribed alongside first-line treatments. Immunosuppressants suppress the inflammatory response, which is what drives uveitis. This means that 45.2% of drug sales for uveitis are expected to be generated by long-acting immunosuppressants in 2029, a rise from 28% in 2019.

Magdalene Crabbe, Senior Pharma Analyst at GlobalData, comments: “Long-acting non-steroidal drugs are the future of therapy in the uveitis space. Uveitis is characterised by ocular inflammation, and immunosuppressants can offer a quick anti-inflammatory response without the risks often associated with corticosteroids. Further, long-acting immunosuppressants work for two or more weeks.”

Uveitis drug sales in the nine major markets (9MM*) are expected to almost triple from $286m in 2019 to $790m in 2029. Sales of long-acting immunosuppressants reached $80m in 2019, and these drugs are expected to generate $357m in 2029.

PR13359 .png

While more chronic and recurrent uveitis patients will experience relief from treatment with long-acting immunosuppressants, a key issue in this therapy area is the need to develop drugs that can be administered by the patient.

Crabbe continues: “The greatest advantage of some immunosuppressants is the fact that they are inserted into the eyes, which reduces the risk of systemic side effects. This is especially important for patients with autoimmune diseases and comorbidities that negatively affect patients’ quality of life.”

*9MM: US, France, Germany, Italy, Spain, UK, Japan, Canada, and Australia

Scope

Overview of epidemiological data, including information about disease duration (acute, chronic, recurrent), localization (anterior, intermediate, posterior, or panuveitis), and etiology (non-infectious, infectious, or idiopathic).

Examination of pathophysiology, symptoms, diagnosis, and disease management.

Annualized forecast of sales of uveitis therapeutics in the 9MM.

Examination of unmet needs, ongoing clinical trials, and profiles of individual marketed drugs.

Assessment of pipeline drugs, including clinical and commercial aspects of each therapy in development for the treatment of uveitis in adults.

Review of key market drivers and barriers.

Discussion of market potential and opportunities for drug developers in the uveitis space.

Key Questions Answered in This Report

– What were the market leading drugs for uveitis in 2019?

– When will the late-stage pipeline products launch in each of the 9MM?

– What are the major clinical and environmental unmet needs in the uveitis market?

– What are the key commercial opportunities for pharmaceutical companies developing therapies for uveitis?

Key Highlights

  • Drugs for non-infectious uveitis generated an estimated $286.3M in 2019, across the 9MM. GlobalData projects that the market will expand at a Compound Annual Growth Rate (CAGR) of 10.7%, reaching $789.7M in 2029.
  • Corticosteroids and immunosuppressants such as methotrexate, azathioprine, and tacrolimus are frequently used to treat patients with uveitis. The main issue with corticosteroids is their potential to cause elevated intraocular pressures and cataracts. Most patients develop these complications after long-term treatment with steroids.
  • Immunosuppressants such as azathioprine and tacrolimus take several weeks to bring about therapeutic outcomes. Humira (adalimumab) was the first biologic to gain approval for the treatment of uveitis. However, the drug is injected subcutaneously, and this has been linked to dermatological side effects and discomfort.
  • Anterior uveitis makes up the majority of diagnosed prevalent cases of the disease. However, symptoms can overlap with conjunctivitis and keratitis. This can lead to misdiagnosis and delayed initiation of effective treatment.
  • A number of drugs that are being developed for uveitis are also in the pipeline for other inflammatory diseases. This is useful because a significant percentage of patients with non-infectious uveitis also have an immune system-related comorbidity.
  • Factors that will contribute to growth in the market include continued use of AbbVie’s Humira for the treatment of both anterior and posterior uveitis, the introduction of non-steroidal therapies for the management of patients with anterior uveitis, and the assumed increase in the number of people who develop recurrent uveitis in line with the growing prevalence of autoimmune conditions.
  • Barriers to growth include the use of inexpensive generic formulations of immunosuppressants in all of the 9MM and lack of compliance among patients who are instructed to apply eye drops up to six times per day.
  • The top-selling late-stage pipeline agent in 2029 will be EYS-606. This is because the drug is expected to be the only gene therapy that will become available to treat anterior uveitis during the forecast window.

Reasons to buy

The report will enable you to:

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the uveitis therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the uveitis therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Companies mentioned

Apothecon

Novartis

Wakamoto

Allergan

Johnson & Johnson

Bausch & Lomb

EyePoint Pharmaceuticals

Alimera

Pfizer

Intrapharm

Baxter Healthcare

Shionogi

Astellas

Janssen

AbbVie

Merck

Roche

Genentech

Mitsubishi Tanabe Pharma

Chugai

Santen

Aciont

Eyevensys

Oculis

Enzo Biochem

Panoptes Pharma

Tarsius Pharma

Alvotech

Dobecure

Mitotech

Sun Pharma

EyeGate Pharma

Amgen

Affibody

Revolo Biotherapeutics

Apitope International

Palatin Technologies

Reven Pharmaceuticals

Table of Contents

Table of Contents

| About GlobalData

1 Uveitis: Executive Summary

1.1 The Uveitis Market Will Almost Triple In Size from 2019-2029

1.2 Steroid-Sparing Immunosuppressive Strategies Increasingly Favored by Clinicians and Patients

1.3 Lack of Novel Therapies for Anterior Uveitis Will Limit Market Growth in Japan, Canada, and Australia

1.4 Strategic Alliances Are a Key Priority for Drug Developers in This Therapy Area

1.5 Focus Is On Label Expansion and Treatment of Comorbidities in the Uveitis Pipeline

1.6 What Do Physicians Think?

2 Introduction

2.1 Catalyst

2.2 Related Reports

2.3 Upcoming Reports

3 Disease Overview

3.1 Etiology and Pathophysiology

3.1.1 Overview

3.1.2 Etiology

3.1.3 Pathophysiology

3.2 Classification or Staging Systems

3.3 Prognosis and Quality of Life

4 Epidemiology

4.1 Disease Background

4.2 Risk Factors and Comorbidities

4.3 Global and Historical Trends

4.4 9MM Forecast Methodology

4.4.1 Sources

4.4.2 Forecast Assumptions and Methods

4.4.3 Forecast Assumptions and Methods: Diagnosed Incident and Diagnosed Prevalent Cases of Uveitis – 9MM

4.4.4 Forecast Assumptions and Methods: Diagnosed Prevalent Cases of Uveitis by Anatomical Site of Inflammation

4.4.5 Diagnosed Prevalent Cases of Uveitis by Etiology

4.4.6 Diagnosed Prevalent Cases of Uveitis by Severity

4.4.7 Diagnosed Prevalent Cases of Uveitis by Laterality

4.5 Epidemiological Forecast for Uveitis

4.5.1 Diagnosed Incident Cases of Uveitis

4.5.2 Age-Specific Diagnosed Incident Cases of Uveitis

4.5.3 Sex-Specific Diagnosed Incident Cases of Uveitis

4.5.4 Diagnosed Prevalent Cases of Uveitis

4.5.5 Age-Specific Diagnosed Prevalent Cases of Uveitis

4.5.6 Sex-Specific Diagnosed Prevalent Cases of Uveitis

4.5.7 Diagnosed Prevalent Cases of Uveitis by Anatomical Site of Inflammation, Etiology, and Severity

4.5.8 Diagnosed Prevalent Cases of Uveitis by Laterality

4.6 Discussion

4.6.1 Epidemiological Forecast Insight

4.6.2 COVID-19 Impact

4.6.3 Limitations of Analysis

4.6.4 Strengths of the Analysis

5 Disease Management

5.1 Diagnosis and Treatment Overview

5.2 Treatment Guidelines

5.3 Pharmacotherapeutic Management of Non-infectious Uveitis

5.3.1 Anterior Uveitis

5.3.2 Intermediate, Posterior, and Panuveitis

5.4 Marketed Drugs by Therapeutic Class

5.4.1 Corticosteroids

5.4.2 Immunosuppressants

5.4.3 Antimuscarinic Agents

5.5 Treatment of Uveitis by Geographic Region

5.5.1 North America

5.5.2 5EU

5.5.3 Asia-Pacific

5.6 KOL Insights on Disease Management

6 Competitive Assessment

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Increasing Disease Awareness Among Physicians and Patients

7.3 Improving the Safety and Side-Effect Profiles of Pharmaceutical Products

7.4 Making Drug Administration More Manageable for Patients

7.5 Standardization of Treatment Guidelines for Different Disease Subtypes

8 R&D Strategies

8.1 Overview

8.1.1 Innovation in the Uveitis Pipeline

8.1.2 Repurposing Biologic Therapies Marketed for Autoimmune Diseases

8.1.3 Optimizing Administration of Immunosuppressants

8.2 Clinical Trials Design

8.2.1 Primary and Secondary Endpoints

8.2.2 Trial Duration and Steroid-Sparing Treatment Strategies

8.2.3 Uveitis as an Add-On Indication

9 Pipeline Assessment

9.1 Overview

9.2 Clinical Trials

9.3 Late-Stage Pipeline Products

9.4 Other Drugs in Clinical Development

10 Pipeline Valuation Analysis

10.1 Overview

10.2 Clinical Benchmarking

10.3 Commercial Benchmarking

10.4 Competitive Assessment

11 Current and Future Players

11.1 Overview

11.2 Trends in Corporate Strategy

11.3 Deal-Making Trends

11.4 Analysis of Company Portfolios in the Uveitis Market

11.4.1 AbbVie and Allergan

11.4.2 Novartis/Alcon

11.5 Analysis of Company Portfolios in the Uveitis Pipeline

11.5.1 Chugai

11.5.2 Aciont

11.5.3 Oculis

11.5.4 Tarsius Pharma

11.5.5 Enzo Biochem

11.5.6 Santen

11.5.7 Eyevensys

11.5.8 Panoptes Pharma

12 Market Outlook

12.1 Global Markets

12.1.1 Forecast

12.1.2 Drivers and Barriers – Global Issues

12.2 US

12.2.1 Forecast

12.2.2 Key Events

12.2.3 Drivers and Barriers

12.3 5EU

12.3.1 Forecast

12.3.2 Key Events

12.3.3 Drivers and Barriers

12.4 Japan

12.4.1 Forecast

12.4.2 Key Events

12.4.3 Drivers and Barriers

12.5 Canada

12.5.1 Forecast

12.5.2 Key Events

12.5.3 Drivers and Barriers

12.6 Australia

12.6.1 Forecast

12.6.2 Key Events

12.6.3 Drivers and Barriers

13 Appendix

13.1 Bibliography

13.2 Abbreviations

13.3 Methodology

13.3.1 Forecasting Methodology

13.3.2 Diagnosed Patients

13.3.3 Percent Drug-Treated Patients

13.3.4 Drugs Included in Each Therapeutic Class

13.3.5 Clinical Positioning of Marketed Drugs

13.3.6 Clinical Positioning of Pipeline Drugs

13.3.7 General Pricing Assumptions

13.3.8 Pricing of Pipeline Agents

13.4 Primary Research – KOLs Interviewed for This Report

13.4.1 KOLs

13.5 Primary Research – Prescriber Survey

13.6 About the Authors

13.6.1 Analyst

13.6.2 Therapy Area Director

13.6.3 Epidemiologist

13.6.4 Managing Epidemiologist

13.6.5 Global Director of Therapy Analysis and Epidemiology

13.6.6 Global Head and EVP of Healthcare Operations and Strategy

13.7 Contact Us

List of Tables

Table 1: Non-infectious Uveitis: Key Metrics in the 9MM

Table 2: SUN Working Group Anatomical Classification of Uveitis

Table 3: SUN Working Group Classification of Uveitis by Disease Onset and Duration

Table 4: Grading of Anterior Chamber Flare and Anterior Chamber Cells

Table 5: Grading of Vitreous Haze

Table 6: Autoimmune Uveitis and Ocular Complications

Table 7: Risk Factors and Comorbidities for Uveitis

Table 8: Diagnosed Prevalent Cases of Uveitis by Anatomical Site of Inflammation, Etiology, and Severity

Table 9: Diagnosed Prevalent Cases of Uveitis by Laterality

Table 10: Treatment Guidelines for Uveitis in the 9MM

Table 11: Uveitis Disease Management – North America

Table 12: Uveitis Disease Management – 5EU

Table 13: Uveitis Disease Management – Japan and Australia

Table 14: Marketed Drugs for Uveitis Across the 9MM

Table 15: Comparison of Therapeutic Classes of Pipeline Drug Candidates for Non-infectious Uveitis, 2019-2029

Table 16: Phase I Pipeline Products in Development for Uveitis

Table 17: AbbVie’s Uveitis Portfolio Assessment, 2021

Table 18: Novartis’ Uveitis Portfolio Assessment, 2021

Table 19: Chugai’s Uveitis Portfolio Assessment, 2021

Table 20: Aciont’s Uveitis Portfolio Assessment, 2021

Table 21: Oculis’ Uveitis Portfolio Assessment, 2021

Table 22: Tarsius Pharma’s Uveitis Portfolio Assessment, 2021

Table 23: Enzo Biochem’s Uveitis Portfolio Assessment, 2021

Table 24: Santen’s Uveitis Portfolio Assessment, 2021

Table 25: Eyevensys’ Uveitis Portfolio Assessment, 2021

Table 26: Panoptes Pharma’s Uveitis Portfolio Assessment, 2021

Table 27: Uveitis Market – Global Drivers and Barriers, 2019-2029

Table 28: Key Events Impacting Sales for Uveitis in the US, 2019-2029

Table 29: Uveitis Market – Drivers and Barriers in the US, 2019-2029

Table 30: Key Events Impacting Sales for Uveitis in the 5EU, 2019-2029

Table 31: Uveitis Market – Drivers and Barriers in the 5EU, 2019-2029

Table 32: Key Events Impacting Sales for Uveitis in Japan, 2019-2029

Table 33: Uveitis Market – Drivers and Barriers in Japan, 2019-2029

Table 34: Key Events Impacting Sales for Uveitis in Canada, 2019-2029

Table 35: Uveitis Market – Drivers and Barriers in Canada, 2019-2029

Table 36: Key Events Impacting Sales for Uveitis in Australia, 2019-2029

Table 37: Uveitis Market – Drivers and Barriers in Australia, 2019-2029

Table 38: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

Figure 1: Global (9MM) Sales Forecast by Geographic Region for Uveitis in 2019 and 2029

Figure 2: Analysis of the Company Portfolio Gap in Uveitis During the Forecast Period

Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of Uveitis During the Forecast Period

Figure 4: Differentiation of Pro-inflammatory T-cells in Non-infectious Uveitis

Figure 5: 9MM, Diagnosed Incidence of Uveitis, Men and Women, Cases Per 100,000 Population, Ages ≥18 Years, 2019

Figure 6: 9MM, Diagnosed Prevalence of Uveitis, Men and Women, %, Ages ≥18 Years, 2019

Figure 7: 9MM, Sources Used and Not Used to Forecast the Diagnosed Incident and Diagnosed Prevalent Cases of Uveitis

Figure 8: 9MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Uveitis by Anatomical Site of Inflammation

Figure 9: 9MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Uveitis by Etiology

Figure 10: 9MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Uveitis by Severity

Figure 11: 9MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Uveitis by Laterality

Figure 12: 9MM, Diagnosed Incident Cases of Uveitis, N, Both Sexes, Ages ≥18 Years, 2019

Figure 13: 9MM, Diagnosed Incident Cases of Uveitis by Age, N, Both Sexes, 2019

Figure 14: 9MM, Diagnosed Incident Cases of Uveitis by Sex, N, Ages ≥18 Years, 2019

Figure 15: 9MM, Diagnosed Prevalent Cases of Uveitis, N, Both Sexes, Ages ≥18 Years, 2019

Figure 16: 9MM, Diagnosed Prevalent Cases of Uveitis by Age, N, Both Sexes, 2019

Figure 17: 9MM, Diagnosed Prevalent Cases of Uveitis by Sex, N, Ages ≥18 Years, 2019

Figure 18: Unmet Needs and Opportunities in Uveitis

Figure 19: Snellen Chart Used to Measure Visual Acuity in Patients With Uveitis

Figure 20: Overview of the Development Pipeline in Uveitis

Figure 21: Key Ongoing Clinical Trials Involving Patients With Non-infectious Uveitis in the 9MM

Figure 22: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of Uveitis During the Forecast Period

Figure 23: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC Ocular Application, Pred Forte

Figure 24: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC Systemic Treatment, Humira

Figure 25: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC Intraocular Preparation, Ozurdex

Figure 26: Analysis of the Company Portfolio Gap in Uveitis During the Forecast Period

Figure 27: Global (9MM) Sales Forecast by Geographic Region for Uveitis in 2019 and 2029

Figure 28: Sales of Corticosteroids for Uveitis in the 9MM, 2019 and 2029

Figure 29: Sales Forecast by Therapeutic Class for Uveitis in the 9MM, 2019 and 2029

Figure 30: Sales Forecast by Therapeutic Class for Uveitis in the US in 2019 and 2029

Figure 31: Sales Forecast by Therapeutic Class for Uveitis in the 5EU in 2019 and 2029

Figure 32: Sales Forecast by Therapeutic Class for Uveitis in Japan in 2019 and 2029

Figure 33: Sales Forecast by Therapeutic Class for Uveitis in Canada in 2019 and 2029

Figure 34: Sales Forecast by Therapeutic Class for Uveitis in Australia in 2019 and 2029

    Pricing

Discounts available for multiple purchases.

reportstore@globaldata.com
+44 20 7947 2745

Join our mailing list

Saved reports